Biological sex and health: X chromosome inactivation and sex differences explored at the Francis Crick Institute

Podcast overview

In this episode, Professor Brian Cox hosts a panel from the Francis Crick Institute to unpack how biological sex shapes health and disease, the science of sex chromosomes, and why research has historically focused on male biology. The discussion covers X chromosome inactivation, mosaicism, sex differences in immune response, and the challenges of including sex as a variable in research and clinical trials.

• Key topic: genetics of sex determination and X inactivation
• Key insight: females are mosaics due to X inactivation, which has implications for disease and treatment
• Key insight: male-centric research has biased our understanding and drug safety in women
• Key insight: data collection and analysis must evolve to include sex as a biological variable

Introduction

The podcast features Professor Brian Cox introducing a Crick Institute panel to examine how biological sex, including chromosomes, hormones and gene expression, affects health and disease. The conversation emphasizes that sex is more than XX versus XY and that biology is complex and variable. A recurring theme is that medicine and science have historically underrepresented female biology, with consequences for diagnosis, progression and treatment of disease.

The genetics of sex: from fertilization to X inactivation

Panelists outline where sex differentiation begins in development, at fertilization when sperm and egg determine XX or XY, followed by the expression of SRY around six to seven weeks that directs testis formation. In the absence of SRY, the default path tends toward ovarian development. Hormones then influence many tissues beyond reproductive organs. Edith Hurt explains that almost every cell contains a sex, and the X chromosome inactivation (XCI) in females creates a mosaic state where maternal and paternal X are expressed in roughly half of cells, a pattern remembered through cell divisions. Natasha Karp notes that about 80% of known cell lines in research are male, a legacy of historical assumptions that hormones were irrelevant to the cell body in vitro. XCI is not absolute; some genes escape silencing and may contribute to sex-biased disease such as autoimmune conditions. The discussion clarifies the concept that XX individuals can have male features, and XY individuals can have female features depending on hormones and other factors, highlighting the complexity of sex beyond a binary view.

What the biology means for disease and treatment

The conversation moves to disease bias by sex, noting that autoimmune diseases are more common in women, with lupus showing a pronounced female bias. Hormonal influences, immune system differences, and genes escaping XCI are discussed as potential drivers. The panel also tackles cardiovascular disease misdiagnosis in women, differences in heart presentation, and the role of menopause and estrogen in modulating risk. The group discusses pain as a target for sex-specific therapies, acknowledging that signaling pathways and inflammation can differ between sexes, potentially calling for sex-specific pain medications and dosing.

Data, trials and regulation

A recurring theme is data collection gaps and analysis challenges. James Matthews asks how gender-affirming hormone therapy might affect disease risk, and the panel concedes that population-level data is limited and long-term studies are needed. There is concern about how to interpret sex differences, when they are biologically meaningful versus statistical artifacts. The discussion covers current regulatory landscapes, the NIH stance on sex as a biological variable, and cautions against simplistic rules. The conversation also emphasizes the role of AI and machine learning, noting that biased data can amplify disparities unless models explicitly account for sex and age, including considerations for pediatric and pregnant populations.

Looking to the future

The panel ends with reflections on AI, digital twins, and the importance of including diverse data sources to better represent population diversity. The speakers advocate for better education of future researchers and clinicians about sex and gender in biology, and for ongoing vigilance to avoid repeating past biases. The dialogue demonstrates a commitment to more nuanced study designs, inclusive trial designs, and the ethical implications of sex-aware research in improving health outcomes for everyone.